drugset / Trial / NCT01373619

Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine

NCT01373619

Phase 4 Completed 150 enrolled University of Campania Luigi Vanvitelli
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Heart failure with normal ejection fraction is often under diagnosed and certainly under treated in hemodialyzed patients. Because of the benefit of reducing heart rate, ivabradine, a pure heart-rate lowering agent without effects on blood pressure, is of potential therapeutic utility.

Timeline

Start
2010-01
Primary completion
2011-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule 7.5 mg

Indications